Option Bears Feel the Sting of Bristol-Myers Squibb Company (BMY) Rally

Short-term Bristol-Myers Squibb Co (BMY) traders have rarely been as put-heavy as they are now

Jan 12, 2015 at 11:06 AM
facebook twitter linkedin


Bristol-Myers Squibb Co (NYSE:BMY) is up 4.4% at $62.98 -- and earlier tagged a fresh 14-year peak of $64.44 -- on news the company's lung cancer drug, Opdivo, met the endpoint goals of its late-stage trial. Today's price action is being met with a rush of call activity in the equity's options pits, with the contracts trading at nearly six times the average intraday pace -- a scenario that runs counter to the withstanding trend.

Specifically, the equity's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.60 ranks in the bearishly skewed 67th annual percentile. Even more telling is BMY's Schaeffer's put/call open interest ratio (SOIR) of 1.21, which ranks just 4 percentage points from a 52-week peak. Simply stated, short-term speculators have rarely been as put-skewed toward BMY as they are now.

Technically speaking, BMY has been in rally mode since hitting its most recent low of $47.54 in mid-October, with the shares up more than 32%. Therefore, it's entirely possible that a portion of the recent put buying is a result of shareholders protecting their paper profits against a pullback. Regardless, the equity's near-term options are currently pricing in lofty volatility expectations, per BMY's Schaeffer's Volatility Index (SVI) of 38%, which ranks higher than all similar readings taken in the past year.

Should Bristol-Myers Squibb Co (NYSE:BMY) extend its positive momentum, a round of upgrades and/or price-target hikes could help fuel the stock's fire. At present, 47% of covering analysts maintain a "hold" or "strong sell" suggestion, while the average 12-month price target of $57.21 stands at a discount to current trading levels.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners